Page 7 - MP-2014v5n1

Basic HTML Version

Molecular Pathogens
4
Table 2 Distribution pattern of antibiogram among the 36
vibrio
strain
S.No
Antibiotic
Used
Conc.,
(μg)
Nature of Antibiogram
Resistance
Intermediate
sensitive
1
Amikacin
30
Nil (0%)
14 (38.88%)
22 (61.11%)
2
Ampicillin
10
36 (100%)
Nil (0%)
Nil (0%)
3
Amoxyclave
30
36 (100%)
Nil (0%)
Nil (0%)
4
Aztreoname
30
3 (8.33%)
9 (25%)
24 (66.66%)
5
Ceftazidime
30
6 (11.11%)
31 (86.11%)
Nil (0%)
6
Cefotaxime
30
Nil (0%)
9 (25%)
27 (75%)
7
Ciprofloxacin
5
Nil (0%)
Nil (0%)
36 (100%)
8
Co- trimoxazole
25
Nil (0%)
Nil (0%)
36 (100%)
9
Erythromycin
15
Nil (0%)
24 (58.33%)
12 (36.11%)
10
Gentamycin
10
Nil (0%)
9 (25%)
27 (75%)
11
Imipenem
10
36 (100%)
Nil (0%)
Nil (0%)
12
Levofloxacin
5
Nil (0%)
Nil (0%)
36 (100%)
13
Methicillin
10
36 (100%)
Nil (0%)
Nil (0%)
14
Nalidixic acid
30
3(8.33%)
5(13.88%)
28 (77.77%)
15
Netillin
30
Nil (0%)
15( 41.66%)
21 (58.33%)
16
Nitrofurantoin
30
36 (100%)
Nil (0%)
Nil (0%)
17
Novobiocin
5
17(47.22%)
16 (44.44%)
3 (8.33%)
18
Tobramycin
10
Nil (0%)
Nil (0%)
36 (100%)
19
Tetracyclin
30
Nil (0%)
Nil (0%)
36 (100%)
20
Vancomycin
30
24 (66.66%)
3 (8.33%)
9 (25%)
36 Isolates of
Vibrio sp
. comprising of 5 genera were
tested against 20 antibiotics. The result of which are
presented in the Table 3. 25 % of
Vibrio sp
., was
totally resistance (100%) towards Ampicillin,
Amoxyclave, imipenam, Methicillin and Nitrofurantoin
while 100% sensitivity was shown by Levofloxacin.
Tobramycin, Tetracyclin. Ciprofloxacin 55 % of the
strains presended intermediate sensitivity against ather
antibiotics such as Amikacin, Aztreoname. Cefotaxime
Ceftazidime, Co-trimoxazole, Erithromycin, Gentamycin,
Nalidic acid, Netillin, Novobiocin, Vancomycin.
Table 3 Antibiotics susceptibility test of
Vibrio
sp. isolated
Vibrio
sp. Isolated from Marketed sea foods sample
Antibiotics used
Conc., (μg)
1
2
3
4
5
6
7
8
9
10
11
12
Amikacin
30
S
D
D
S
D
S
S
S
S
D
S
D
Ampicillin
10
R
R
R
R
R
R
R
R
R
R
R
R
Amoxyclave
30
R
R
R
R
R
R
R
R
R
R
R
R
Aztreoname
30
R
R
D
R
R
R
R
R
R
D
R
D
Ceftazidime
30
D
D
D
D
D
D
D
D
D
D
D
D
Cefotaxime
30
D
S
S
D
S
S
D
S
D
S
S
S
Ciprofloxacin
5
S
S
S
S
S
S
S
S
S
S
S
S
Co
-
trimoxazole
5
S
S
S
S
S
S
S
S
S
S
S
S
Erythromycin
15
S
D
D
S
D
D
S
D
S
D
D
D
Gentamycin
10
D
S
S
D
S
S
D
S
D
S
S
S
Imipenem
10
R
R
R
R
R
R
R
R
R
R
R
R
Levofloxacin
5
S
S
S
S
S
S
S
S
S
S
S
S
Methicillin
10
R
R
R
R
R
R
R
R
R
R
R
R
Nalidixic acid
30
S
S
S
S
S
S
S
S
S
S
S
S
Netillin
30
D
S
S
D
S
S
D
S
D
S
S
S
Nitrofurantoin
30
R
R
R
R
R
R
R
R
R
R
R
R
Novobiocin
5
R
R
D
R
R
D
R
D
R
D
D
D
Tobramycin
10
S
S
S
S
S
S
S
S
S
S
S
S
Tetracyclin
30
S
S
S
S
S
S
S
S
S
S
S
S
Vancomycin
30
S
R
S
S
R
S
S
S
S
S
S
S
Note: (R)
-
Resistant (13
-
14mm), (D) – Intermediate (16
-
20mm), (S)
-
Sensitive(21
-
30mm). 13
-
V. vulnificus
, 14
-
V. mimicus,15
-
V.
alginolyticus
,1 6
-
V. vulnificus
, 17
-
V. mimicus
, 18
-
V. parahaemolyticus,
19
-
V. vulnificus
,20
-
V.parahaemolyticus
, 21
-
V. vulnificus
,
22
-
V. alginolyticus
, 23
-
V. parahaemolyticus,24
.
V alginolyticus